CDKN2A and neoplasm: These mutations may occur in receptors (e.g., KITKIT), effectors (BRAF, NRAS), or inhibitors (NF1, RASA2, CDKN2A, SPRED1) of the pathway, leading to proliferation of transformed melanocytes, abnormal differentiation, and persistent survival with impaired apoptosis of tumour cells.